London Health, Biotech & Nutrition R&D Companies Directory

The Cell and Gene Therapy Catapult is a not-for-profit organisation established to accelerate the development and commercialisation of advanced therapy medicinal products (ATMPs) in the UK. They provide infrastructure, technical expertise, and collaborative platforms to bridge the gap between academic research and industrial manufacturing. Their work has evolved from foundational process development to leading large-scale national networks for regulatory innovation, robotic automation, and sustainable manufacturing.

King's College London is a world-leading academic institution that conducts extensive interdisciplinary research across medical, digital, and social sciences. Their grant history demonstrates a strong focus on translating fundamental research into real-world applications, particularly in AI-driven healthcare, neurotechnology, cybersecurity, and democratic governance. The university frequently collaborates with NHS trusts, industrial partners, and international consortia to address complex societal challenges through rigorous scientific and policy-oriented innovation.

The Cell and Gene Therapy Catapult is a specialist organisation established to accelerate the development and commercialisation of advanced therapy medicinal products in the UK. They provide critical infrastructure, manufacturing expertise, and coordination services to bridge the gap between laboratory research and clinical adoption. Their work focuses on building the industrial ecosystem required to deliver cell and gene therapies to patients at scale.

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in oncology, rare diseases, and biopharmaceuticals. Their grant history demonstrates a strategic shift toward digital transformation, sustainable manufacturing, and advanced predictive modelling to improve drug efficacy and environmental impact. They frequently collaborate with academic institutions and specialist technology partners to integrate robotics, AI, and genomic sequencing into their R&D and production pipelines.

Genomics England is a government-owned company established to deliver the 100,000 Genomes Project and advance the clinical application of genomic medicine within the NHS. They develop large-scale data infrastructure and analytical frameworks to integrate whole genome sequencing into routine clinical care and cancer research. Their work focuses on bridging the gap between complex genomic data and actionable clinical insights for patient benefit.

Autolus is a clinical-stage biopharmaceutical company specialising in the development of next-generation programmed T-cell therapies for the treatment of cancer. Their work focuses on engineering CAR T-cell products that target both liquid and solid tumours, while simultaneously addressing the complex manufacturing and supply chain challenges inherent in personalised medicine. Over their grant history, they have evolved from fundamental research into CAR T-cell mechanisms to leading large-scale industrial consortia focused on the digitalisation and standardisation of advanced therapy manufacturing processes.

Bactobio discovers novel antibiotics and fungicides from previously unculturable microbes using synthetic biology, next-generation sequencing, and machine learning. The company addresses antimicrobial resistance and crop diseases by accessing the 99% of microbes that cannot be cultured in the lab, screening for new bioactive compounds. Their work has evolved from targeted antibiotic discovery to broad high-throughput screening with AI integration.

Oxford Heartbeat is a medical technology company that develops AI-powered software for pre-operative planning and rehearsal of stent placements in cardiovascular surgeries. Their flagship product, PreSize, uses computational modelling to predict stent behaviour within patient-specific anatomy, helping clinicians select the best device and reducing surgical complications. The company has evolved from early feasibility studies to a CE-marked, clinically validated medical device software platform, supported by a strong portfolio of Innovate UK grants.

Health Data Research UK is the national institute for health data science, focusing on the development of secure research environments and data infrastructure to facilitate the secondary use of sensitive health information. Their work involves establishing interoperability standards, quality labelling mechanisms, and federated access models to support large-scale research across European networks. They operate as a strategic hub, coordinating complex multi-stakeholder initiatives to improve the utility and governance of health datasets.

Oxford Drug Design is a micro enterprise specialising in the development of novel antibiotics to combat antimicrobial resistance. The company works on dual-target tRNA synthetase inhibitors and veterinary-specific antibiotics, using computational chemgenomics to minimise resistance development. Its portfolio spans human and animal health applications, with recent work focusing on pig farming.

Entocycle develops automated insect rearing and processing systems for industrial-scale production of black soldier fly (BSF) protein and biofertiliser from organic waste. Their technology covers breeding, rearing, and downstream processing, aiming to replace fishmeal and soy in animal feed. Their work has evolved from early feasibility studies in Brazil to leading large collaborative projects to establish the UK insect farming industry.

Good Boost Wellbeing is a medical technology social enterprise that delivers AI-personalised rehabilitation exercise for people living with musculoskeletal (MSK) conditions. Their technology, initially developed for aquatic settings, now includes home-based and gym-based solutions leveraging computer vision and gamification to improve accessibility and engagement. Partnering with major MSK charities and universities, the company aims to reduce pressure on the NHS by scaling community-based rehabilitation services.

Modern Biosciences is a biotechnology company developing small molecule therapeutics for fibrotic and neurodegenerative diseases. Their lead asset, MBS2320, is a metabolic reprogramming agent designed to promote myelin regeneration and anti-inflammatory effects, with preclinical evidence showing anti-fibrotic and pro-repair activity in Idiopathic Pulmonary Fibrosis (IPF). The company's grant history focuses on demonstrating proof of concept for this first-in-class agent.

Freeline Therapeutics is a UK-based gene therapy company developing adeno-associated virus (AAV) vector-based treatments for rare bleeding and metabolic disorders. Their work has evolved from establishing commercial-scale manufacturing capabilities to developing shared scalable production platforms and advancing specific therapies for Fabry disease and rare kidney diseases, collaborating extensively with Cell and Gene Therapy Catapult, Gyroscope Therapeutics, and academic partners.

Epsilogen (formerly IGEM Therapeutics) is a biotechnology company developing IgE-based antibodies for cancer immunotherapy. Their technology leverages the unique anti-cancer mode of action of IgE antibodies to target solid tumours, with a focus on HER2 and FRa antigens. The company has progressed from early discovery through to preclinical validation, moving towards clinical development.

Orthonika is a spin-out from Imperial College London developing a synthetic total meniscus replacement for the knee using novel load-bearing hydrogels and textile-reinforced composites. The company aims to address the high prevalence of meniscal injuries and the inadequacy of current treatments like meniscectomy, which can lead to osteoarthritis. Over six Innovate UK grants, Orthonika has progressed from early-stage R&D through manufacturing development to pre-clinical studies and scaffold integration, targeting first-in-human clinical trials.

Pharmidex Pharmaceutical Services is a London-based small enterprise providing drug delivery and formulation services for novel therapeutics. The company specialises in nanomedicine, biologics, and advanced therapy manufacturing, collaborating extensively with academic and industrial partners to address neurological, oncological, and inflammatory diseases. Their grant history shows a progression from early nanomedicine prototypes to siRNA delivery and cell therapies, with a strong focus on targeted delivery systems.

Guy's and St Thomas' NHS Foundation Trust is a leading UK healthcare provider that integrates clinical excellence with advanced research and innovation. The Trust actively develops and validates medical technologies, ranging from AI-driven diagnostic tools for macular disease to metagenomic sequencing devices for intensive care. Through its leadership in national accelerator programmes, the organisation plays a pivotal role in scaling early-stage FemTech and MedTech ventures within the UK health ecosystem.

WeWALK develops a smart cane attachment that screws onto a standard white cane, using sensors to detect obstacles from knee to head height. The device connects to a smartphone app providing audio navigation via Google Maps and other services, aiming to improve independent mobility for visually impaired individuals. Over six grants, WeWALK has progressed from indoor navigation R&D to clinical validation of its next-generation navigation aid.

LabGenius is a biotechnology company that develops a proprietary machine learning-driven platform, EVA, to automate the discovery and design of novel protein therapeutics. By integrating synthetic biology, robotic automation, and advanced machine learning, the company explores protein fitness landscapes to optimise drug properties for complex diseases. Their work has evolved from early industrial enzyme expression systems to a sophisticated, data-led engine for developing next-generation cancer and inflammatory disease treatments.